XRAY - DENTSPLY SIRONA Inc Stock Price, Fair Value and News

30.68USD-0.12 (-0.39%)Delayed as of 17 Apr 2024, 02:20 pm ET

Market Summary

USD30.68-0.12

Delayedas of 17 Apr 2024, 02:20 pm

-0.39%

XRAY Stock Price

View Fullscreen

XRAY RSI Chart

XRAY Valuation

Market Cap

6.4B

Price/Earnings (Trailing)

-47.49

Price/Sales (Trailing)

1.61

EV/EBITDA

206.55

Price/Free Cashflow

16.94

XRAY Price/Sales (Trailing)

XRAY Profitability

EBT Margin

-4.41%

Return on Equity

-4.08%

Return on Assets

-1.82%

Free Cashflow Yield

5.9%

XRAY Fundamentals

XRAY Revenue

Revenue (TTM)

4.0B

Rev. Growth (Yr)

2.95%

Rev. Growth (Qtr)

6.86%

XRAY Earnings

Earnings (TTM)

-134.5M

Earnings Growth (Yr)

563.33%

Earnings Growth (Qtr)

126.13%

Breaking Down XRAY Revenue

52 Week Range

30.6243.24

(Low)(High)

Last 7 days

-6.2%

Last 30 days

-6.2%

Last 90 days

-13.3%

Trailing 12 Months

-24.7%

How does XRAY drawdown profile look like?

XRAY Financial Health

Current Ratio

1.38

Debt/Equity

0.55

Debt/Cashflow

0.21

XRAY Investor Care

Dividend Yield

1.82%

Dividend/Share (TTM)

0.56

Buy Backs (1Y)

3.71%

Diluted EPS (TTM)

-0.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.9B	3.9B	3.9B	4.0B
2022	4.2B	4.1B	4.0B	3.9B
2021	3.5B	4.0B	4.2B	4.2B
2020	4.0B	3.5B	3.4B	3.3B
2019	4.0B	3.9B	4.0B	4.0B
2018	4.0B	4.1B	4.0B	4.0B
2017	3.9B	3.8B	3.9B	4.0B
2016	2.8B	3.1B	3.4B	3.7B
2015	2.8B	2.8B	2.7B	2.7B
2014	2.9B	3.0B	3.0B	2.9B
2013	2.9B	2.9B	3.0B	3.0B
2012	2.7B	2.8B	2.9B	2.9B
2011	2.2B	2.3B	2.4B	2.5B
2010	2.2B	2.2B	2.2B	2.2B
2009	2.1B	2.1B	2.1B	2.2B
2008	0	2.1B	2.1B	2.2B
2007	0	0	0	2.0B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of DENTSPLY SIRONA Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 12, 2024	johnson robert anthony	acquired	-	-	354	svp, chief supply chain office
Apr 12, 2024	lucier gregory t	acquired	-	-	26.426	-
Apr 12, 2024	frank andreas g	acquired	-	-	503	exec vp/chief business officer
Apr 12, 2024	mazelsky jonathan jay	acquired	-	-	26.426	-
Apr 12, 2024	campion simon d	acquired	-	-	1,088	president, ceo & member of bod
Apr 12, 2024	brandt eric	acquired	-	-	72.546	-
Apr 12, 2024	rosenzweig richard c	acquired	-	-	215	svp, corp dev, gc & secretary
Apr 12, 2024	coleman glenn	acquired	-	-	302	executive vp & cfo
Apr 12, 2024	wagner richard m	acquired	-	-	41.653	vp, chief accounting officer
Apr 12, 2024	holden betsy d	acquired	-	-	129	-

Which funds bought or sold XRAY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	new	-	3,950	3,950	-%
Apr 15, 2024	Sound Income Strategies, LLC	unchanged	-	-1,905	26,353	-%
Apr 15, 2024	STONEBRIDGE CAPITAL MANAGEMENT INC	reduced	-0.05	-119,000	1,637,000	0.73%
Apr 15, 2024	BEACH INVESTMENT COUNSEL INC/PA	unchanged	-	-	787,000	0.10%
Apr 15, 2024	OLD NATIONAL BANCORP /IN/	added	11.41	9,166	244,344	0.01%
Apr 15, 2024	WEST PACES ADVISORS INC.	sold off	-100	-783	-	-%
Apr 12, 2024	AdvisorNet Financial, Inc	sold off	-100	-1,495	-	-%
Apr 12, 2024	BALDWIN BROTHERS LLC/MA	unchanged	-	-1,524	21,076	-%
Apr 12, 2024	DNB Asset Management AS	sold off	-100	-720,270	-	-%
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	unchanged	-	-151	2,091	-%

Are Funds Buying or Selling XRAY?

Are funds buying XRAY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XRAY

No. of Funds

Unveiling DENTSPLY SIRONA Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	11.89%	25,187,041	SC 13G/A
Feb 12, 2024	artisan partners limited partnership	6.1%	12,944,034	SC 13G/A
Feb 05, 2024	nuance investments, llc	5.48%	11,603,889	SC 13G/A
Jan 29, 2024	blackrock inc.	6.2%	13,136,945	SC 13G/A
Feb 13, 2023	generation investment management llp	2.21%	4,747,746	SC 13G/A
Feb 10, 2023	artisan partners limited partnership	6.3%	13,582,284	SC 13G/A
Feb 09, 2023	vanguard group inc	11.69%	25,121,756	SC 13G/A
Feb 08, 2023	nuance investments, llc	5.88%	12,642,319	SC 13G
Feb 03, 2023	blackrock inc.	7.9%	16,978,584	SC 13G/A
Mar 09, 2022	blackrock inc.	10.9%	23,745,567	SC 13G/A

Recent SEC filings of DENTSPLY SIRONA Inc

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading

Peers (Alternatives to DENTSPLY SIRONA Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	189.6B	40.1B	-5.40%	4.53%	33.12	4.73	-8.12%	-17.45%
BDX	66.7B	19.5B	-2.42%	-9.87%	53.13	3.42	4.02%	-22.04%
ALGN	22.9B	3.9B	-2.94%	-12.25%	51.49	5.93	3.42%	23.09%
BAX	20.1B	14.8B	-4.93%	-7.94%	7.56	1.36	2.12%	209.17%
MID-CAP
HSIC	9.2B	12.3B	-4.49%	-14.03%	22	0.74	-2.44%	-22.68%
ATR	9.2B	3.5B	-1.69%	15.70%	32.17	2.62	4.97%	18.89%
BIO	8.5B	2.7B	-12.27%	-39.23%	-13.41	3.2	-4.68%	82.43%
XRAY	6.4B	4.0B	-6.21%	-24.72%	-47.49	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-0.75%	15.36%	-565.58	9.37	33.86%	89.83%
PDCO	2.3B	6.6B	-5.91%	-4.69%	11.86	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.61%	-18.37%	-1.88	0.4	7.73%	-1066.14%
ANIK	380.0M	166.7M	0.59%	-11.05%	-4.6	2.28	6.67%	-456.34%
ANGO	260.4M	324.0M	21.04%	-28.41%	-1.35	0.8	-3.19%	-337.41%
APYX	48.2M	52.3M	-22.35%	-53.67%	-2.57	0.92	17.61%	19.28%
AEMD	3.8M	3.7M	-16.76%	269.23%	-0.31	1.01	5.77%	8.23%

DENTSPLY SIRONA Inc News

Latest updates

DENTSPLY SIRONA Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	6.9%	1,012	947	1,028	978	983	947	1,023	969	1,103	1,040	1,062	1,026	1,076	883	499	881	1,112	962	1,009	946	1,060
Gross Profit	5.5%	522	495	550	519	517	508	581	521	604	569	595	579	567	432	182	475	611	514	541	500	525
S&GA Expenses	9.9%	409	372	416	416	402	401	410	376	377	395	393	386	373	313	259	357	325	399	431	432	433
R&D Expenses	-6.5%	43.00	46.00	49.00	46.00	43.00	41.00	45.00	45.00	49.00	39.00	43.00	40.00	38.00	29.00	20.00	36.00	-	-	-	-	-
EBITDA Margin	369.4%	0.01*	0.00*	-0.26*	-0.25*	-0.22*	-0.18*	0.15*	0.16*	0.17*	0.17*	0.16*	0.12*	0.04*	-	-	-	-	-	-	-	-
Interest Expenses	27.8%	23.00	18.00	21.00	19.00	24.00	14.00	15.00	12.00	18.00	14.00	15.00	14.00	14.00	14.00	11.00	7.00	7.00	7.00	8.00	8.00	9.00
Income Taxes	-193.7%	-15.00	16.00	-39.00	-5.00	23.00	-164	18.00	18.00	37.00	29.00	35.00	33.00	24.00	9.00	-22.00	12.00	35.00	22.00	11.00	15.00	76.00
Earnings Before Taxes	122.8%	57.00	-250	46.00	-28.00	8.00	-1,241	91.00	87.00	156	113	131	145	129	57.00	-114	-122	130	107	48.00	54.00	78.00
EBT Margin	22.4%	-0.04*	-0.06*	-0.31*	-0.30*	-0.27*	-0.22*	0.11*	0.12*	0.13*	0.12*	0.11*	0.06*	-0.01*	-	-	-	-	-	-	-	-
Net Income	126.1%	70.00	-266	85.00	-23.00	-15.00	-1,077	73.00	69.00	119	84.00	96.00	112	105	47.00	-91.00	-134	102	85.00	36.00	39.00	2.00
Net Income Margin	39.0%	-0.03*	-0.06*	-0.26*	-0.27*	-0.24*	-0.20*	0.08*	0.09*	0.10*	0.09*	0.09*	0.05*	-0.02*	-	-	-	-	-	-	-	-
Free Cashflow	19.4%	160	134	104	-58.25	105	109	173	-	187	-	-	27.00	242	176	144	-40.75	269	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	2.3%	7,370	7,201	7,650	7,673	7,643	7,522	8,948	9,172	9,239	9,289	9,378	9,137	9,350	8,896	8,604	8,058	8,603	8,367	8,575	8,605	8,687
Current Assets	3.1%	1,973	1,913	1,920	1,943	1,893	1,939	1,885	1,897	1,852	1,805	1,785	1,696	1,798	2,580	2,363	1,805	2,000	1,811	1,828	1,796	1,888
Cash Equivalents	8.1%	334	309	295	318	365	418	362	374	339	281	332	318	438	1,272	1,109	236	405	226	250	225	310
Inventory	-4.1%	624	651	657	659	627	592	581	553	515	548	539	1.00	476	489	549	591	562	605	608	618	599
Net PPE	-100.0%	-	753	772	770	761	714	744	771	773	771	769	758	791	772	772	777	802	783	820	854	871
Goodwill	2.7%	2,438	2,374	2,703	2,701	2,688	2,584	3,858	3,944	3,976	4,000	4,033	3,952	3,986	3,283	3,227	3,192	3,397	3,356	3,413	3,399	3,431
Liabilities	6.4%	4,076	3,830	3,948	4,035	3,831	3,908	4,110	4,308	4,242	4,226	4,301	4,207	4,415	4,134	3,959	3,368	3,508	3,308	3,392	3,495	3,554
Current Liabilities	17.0%	1,425	1,218	1,271	1,374	1,170	1,296	1,241	1,372	1,261	1,199	1,251	1,212	1,372	1,178	763	892	995	869	881	871	1,013
Long Term Debt	-0.4%	1,796	1,803	1,841	1,842	1,826	1,737	1,807	1,872	1,913	1,925	1,946	1,923	1,978	1,930	2,183	1,421	1,433	1,404	1,441	1,545	1,565
LT Debt, Non Current	-0.4%	1,796	1,803	1,841	1,842	1,826	1,737	1,807	1,872	1,913	1,925	1,946	1,923	1,978	1,930	2,183	1,421	1,433	1,404	1,441	1,545	1,565
Shareholder's Equity	-2.4%	3,293	3,375	3,702	3,638	3,811	3,614	4,838	4,864	4,997	5,063	5,034	4,890	4,935	4,720	4,608	4,649	5,048	5,059	5,183	5,110	5,083
Retained Earnings	22.8%	205	167	463	407	456	498	1,602	1,556	1,514	1,419	1,402	1,328	1,198	1,156	1,125	1,242	1,404	1,324	1,262	1,245	1,226
Additional Paid-In Capital	0.0%	6,643	6,645	6,648	6,604	6,629	6,619	6,617	6,573	6,606	6,659	6,638	6,618	6,604	6,592	6,577	6,554	6,587	6,567	6,551	6,520	6,522
Shares Outstanding	-2.2%	207	212	212	213	215	216	216	217	217	219	219	219	219	-	-	-	-	-	-	-	-
Minority Interest	125.0%	1.00	-4.00	-4.00	-3.00	1.00	1.00	1.00	1.00	1.00	3.00	3.00	3.00	3.00	2.00	2.00	3.00	2.00	2.00	2.00	2.00	12.00
Float	-	-	-	8,463	-	-	-	7,665	-	-	-	13,791	-	-	-	9,606	-	-	-	13,062	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	19.4%	160	134	104	-21.00	142	109	173	93.00	-	-	-	-	264	221	174	-10.00	306	159	145	29.00	202
Share Based Compensation	550.0%	13.00	2.00	14.00	17.00	12.00	14.00	22.00	11.00	-6.00	22.00	19.00	13.00	11.00	17.00	9.00	10.00	16.00	15.00	25.00	9.00	6.00
Cashflow From Investing	-900.0%	-20.00	-2.00	-30.00	-37.00	-29.00	-26.00	-40.00	-43.00	-	-	-	-	-1,101	-25.00	36.00	-16.00	-29.30	-15.20	-11.80	-12.70	-48.00
Cashflow From Financing	-17.4%	-128	-109	-87.00	17.00	-161	-6.00	-152	-10.00	-	-	-	-53.00	-15.00	-37.00	658	-130	-101	-160	-110	-99.20	-78.80
Dividend Payments	3.4%	30.00	29.00	30.00	27.00	26.00	27.00	27.00	24.00	24.00	24.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	20.00	20.00	20.00	20.00
Buy Backs	-	150	-	-	150	-	-	-	150	110	-	-	90.00	-	-	-	140	100	100	60.00	-	-0.20

XRAY Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net sales	$ 3,965	$ 3,922	$ 4,231
Cost of products sold	1,879	1,795	1,884
Gross profit	2,086	2,127	2,347
Selling, general, and administrative expenses	1,613	1,589	1,551
Research and development expenses	184	174	171
Goodwill and intangible asset impairments	307	1,287	0
Restructuring and other costs	67	14	17
Operating (loss) income	(85)	(937)	608
Other income and expenses:
Interest expense, net	81	65	61
Other expense (income), net	9	53	2
(Loss) income before income taxes	(175)	(1,055)	545
(Benefit) provision for income taxes	(43)	(105)	134
Net (loss) income	(132)	(950)	411
Less: Net income (loss) attributable to noncontrolling interests	0	0	0
Net (loss) income attributable to Dentsply Sirona	$ (132)	$ (950)	$ 411
Net (loss) income per common share attributable to Dentsply Sirona:
Basic (in dollars per share)	$ (0.62)	$ (4.41)	$ 1.88
Diluted (in dollars per share)	$ (0.62)	$ (4.41)	$ 1.87
Weighted average common shares outstanding:
Basic (in shares)	212.0	215.5	218.4
Diluted (in shares)	212.0	215.5	220.2

XRAY Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 334	$ 365
Accounts and notes receivable-trade, net	695	632
Inventories, net	624	627
Prepaid expenses and other current assets	320	269
Total Current Assets	1,973	1,893
Property, plant and equipment, net	800	761
Operating lease right-of-use assets, net	178	200
Identifiable intangible assets, net	1,705	1,903
Goodwill, net	2,438	2,688
Other noncurrent assets	276	198
Total Assets	7,370	7,643
Current Liabilities:
Accounts payable	305	279
Accrued liabilities	749	727
Income taxes payable	49	46
Notes payable and current portion of long-term debt	322	118
Total Current Liabilities	1,425	1,170
Long-term debt	1,796	1,826
Operating lease liabilities	125	149
Deferred income taxes	228	287
Other noncurrent liabilities	502	399
Total Liabilities	4,076	3,831
Commitments and contingencies (Note 21)
Equity:
Preferred stock, $1.00 par value; 0.25 million shares authorized; no shares issued	0	0
Common stock, $0.01 par value; 400.0 million shares authorized at December 31, 2023 and 2022 264.5 million shares issued at December 31, 2023 and 2022 215.3 million and 215.3 million shares outstanding at December 31, 2023 and 2022, respectively	3	3
Capital in excess of par value	6,643	6,629
Retained earnings	205	456
Accumulated other comprehensive loss	(636)	(628)
Treasury stock, at cost, 57.3 million and 49.3 million shares at December 31, 2023 and 2022, respectively	(2,922)	(2,649)
Total Dentsply Sirona Equity	3,293	3,811
Noncontrolling interests	1	1
Total Equity	3,294	3,812
Total Liabilities and Equity	$ 7,370	$ 7,643

About DENTSPLY SIRONA Inc

DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies for professional dental market worldwide. The company operates through two segments, Technologies & Equipment, and Consumables. The Technologies & Equipment segment provides dental equipment, such as treatment centers, imaging equipment, motorized dental handpieces, and other instruments for dental practitioners and specialists; dental CAD/CAM technologies for dental offices to support various digital dental procedures, including dental restorations; dentist-directed aligner solutions, SureSmile, and direct-to-consumer clear aligner solutions, as well as high frequency vibration technology device; implants; and urology catheters and other healthcare-related consumable products. The Consumables segment offers endodontic products comprising drills, filers, sealers, irrigation needles, and other tools or single-use solutions, which support root canal procedures; restorative products that include artificial teeth, dental ceramics, digital dentures, precious metal dental alloys, and crown and bridge porcelain products. It also provides small equipment products, which comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers, as well as dental anesthetics, prophylaxis paste, dental sealants, impression materials, teeth whiteners, and topical fluoride. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.

CEO	Mr. Simon D. Campion
WEBSITE	dentsplysirona.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	15000

DENTSPLY SIRONA Inc Frequently Asked Questions

What is the ticker symbol for DENTSPLY SIRONA Inc? What does XRAY stand for in stocks?

XRAY is the stock ticker symbol of DENTSPLY SIRONA Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of DENTSPLY SIRONA Inc (XRAY)?

As of Tue Apr 16 2024, market cap of DENTSPLY SIRONA Inc is 6.39 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XRAY stock?

You can check XRAY's fair value in chart for subscribers.

What is the fair value of XRAY stock?

You can check XRAY's fair value in chart for subscribers. The fair value of DENTSPLY SIRONA Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of DENTSPLY SIRONA Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XRAY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is DENTSPLY SIRONA Inc a good stock to buy?

The fair value guage provides a quick view whether XRAY is over valued or under valued. Whether DENTSPLY SIRONA Inc is cheap or expensive depends on the assumptions which impact DENTSPLY SIRONA Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XRAY.

What is DENTSPLY SIRONA Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, XRAY's PE ratio (Price to Earnings) is -47.49 and Price to Sales (PS) ratio is 1.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XRAY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on DENTSPLY SIRONA Inc's stock?

In the past 10 years, DENTSPLY SIRONA Inc has provided -0.032 (multiply by 100 for percentage) rate of return.